Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / AKBA - Akebia delaying Q2 earnings filing; vadadustat Q3 NDA resubmission on track

AKBA - Akebia delaying Q2 earnings filing; vadadustat Q3 NDA resubmission on track

Akebia Therapeutics Inc.

2023-08-10 18:12:40 ET

  • Akebia Therapeutics ( NASDAQ: AKBA ) said it will delay filing of its Q2 financial results due to accounting errors relating to recording and reporting of return reserves for Auryxia.
  • However, the biopharma said that it is still on track to resubmit an NDA for vadadustat as a treatment for anemia due to chronic kidney disease this quarter as planned.
  • Akebia ( AKBA ) also reiterated net product revenue guidance of $175M-$180M. The consensus for total revenue is $203.4M.
  • The company also noted it believes it has enough cash on hand to fund operations through the next year.

For further details see:

Akebia delaying Q2 earnings filing; vadadustat Q3 NDA resubmission on track
Stock Information
Company Name: Akebia Therapeutics Inc.
Stock Symbol: AKBA
Market: NASDAQ
Website: akebia.com
Menu
AKBA AKBA Quote AKBA Short AKBA News AKBA Articles AKBA Message Board
Get AKBA Alerts

News, Short Squeeze, Breakout and More Instantly...